Payment overview · 2025
General Payments
$397.45
20 reported records · 10 companies
Healthcare provider profile · identity verified
Charles G Morgan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MONROE, LA · NPI 1477541696
Verified facts
What the public records show
CMS Open Payments records show Charles G Morgan, M.D. received $397.45 in general payments during 2025 across 20 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.58 | 17.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.11 | 14.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.68 | 13.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $50.79 | 12.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.58 | 10.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.35 | 9.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $35.34 | 8.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.11 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.96 | 4.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.95 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $397.45 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.58 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.11 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.68 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.68 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $50.79 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 445 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 120 |
| Losartan Potassium | Losartan Potassium | 321 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 99 |
| Omeprazole | Omeprazole | 276 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 86 |
| Gabapentin | Gabapentin | 245 | 80 |
| Clonazepam | Clonazepam | 243 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 79 |
| Tramadol Hcl | Tramadol Hcl | 191 | 61 |
| Alprazolam | Alprazolam | 168 | 34 |
| Eliquis | Apixaban | 165 | 31 |
| Simvastatin | Simvastatin | 164 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 35 |
| Potassium Chloride | Potassium Chloride | 135 | 37 |
| Lorazepam | Lorazepam | 131 | 33 |
| Sertraline Hcl | Sertraline Hcl | 127 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 34 |
| Metformin Hcl | Metformin Hcl | 106 | 43 |
| Furosemide | Furosemide | 105 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 33 |
| Trazodone Hcl | Trazodone Hcl | 101 | 32 |
| Ozempic | Semaglutide | 100 | 21 |
| Temazepam | Temazepam | 100 | 17 |
| Meloxicam | Meloxicam | 99 | 36 |
| Lisinopril | Lisinopril | 98 | 34 |
| Montelukast Sodium | Montelukast Sodium | 91 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 28 |
| Mounjaro | Tirzepatide | 87 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 56 |
| Bumetanide | Bumetanide | 72 | 25 |
| Nifedipine Er | Nifedipine | 69 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 17 |
| Telmisartan | Telmisartan | 68 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 20 |
| Glimepiride | Glimepiride | 66 | 21 |
| Allopurinol | Allopurinol | 65 | 20 |
| Atenolol | Atenolol | 64 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 50 |
| Donepezil Hcl | Donepezil Hcl | 61 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 25 |
| Estradiol | Estradiol | 60 | 23 |
| Celecoxib | Celecoxib | 59 | 26 |
| Prednisone | Prednisone | 59 | 26 |
| Bupropion Xl | Bupropion Hcl | 57 | 17 |
| Diazepam | Diazepam | 52 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Jardiance | Empagliflozin | 47 | 17 |
| Pregabalin | Pregabalin | 46 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Fluconazole | Fluconazole | 44 | 17 |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Spironolactone | Spironolactone | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 12 |
| Finasteride | Finasteride | 38 | 14 |
| Sotalol | Sotalol Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 19 |
| Valsartan | Valsartan | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 30 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 20 |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Fentanyl | Fentanyl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 18 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Ramipril | Ramipril | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Sotalol Af | Sotalol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Nisoldipine | Nisoldipine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $397.45 · 20 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, CAPLYTA, CAPVAXIVE, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Ozempic, PROLIA, Rybelsus, TRINTELLIX, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error